Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Pasoon Hellamand; Marleen G H Van de Sande; Lykke Midtbøll Ørnbjerg; Thomas Klausch; N Trokovic; Tuulikki Sokka-Isler; R Van Vollenhoven; D.C. Nordström; MJ Santos; Elsa Vieira-Sousa; A. G. Loft; Bente Glintborg; Mikkel Østergaard; U Lindström; Johan Karlsson Wallman; Brigitte Michelsen; B. Moeller; Raphael  Micheroli; Catalin Codreanu; C Moogosan; Karin Laas; Z Roter; Karen Minde Fagerli; M Tomsic; I Castrejon; M Pombo-Suarez; B Gudbjörnsson; T Love; K. Pavelka; Jakub Závada; G Kenar; H Yarkan-Tugsai; Merete Lund Hetland; I Van der Horst- Bruinsma

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Pasoon Hellamand, Marleen G H Van de Sande, Lykke Midtbøll Ørnbjerg, Thomas Klausch, N Trokovic, Tuulikki Sokka-Isler, R Van Vollenhoven, D.C. Nordström, MJ Santos, Elsa Vieira-Sousa, A. G. Loft, Bente Glintborg, Mikkel Østergaard, U Lindström, Johan Karlsson Wallman, Brigitte Michelsen, B. Moeller, Raphael Micheroli, Catalin Codreanu, C MoogosanKarin Laas, Z Roter, Karen Minde Fagerli, M Tomsic, I Castrejon, M Pombo-Suarez, B Gudbjörnsson, T Love, K. Pavelka, Jakub Závada, G Kenar, H Yarkan-Tugsai, Merete Lund Hetland, I Van der Horst- Bruinsma

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Abstract

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the EuroSpA research collaboration network

Originalsprog	Engelsk
Publikationsdato	2022
Status	Udgivet - 2022
Begivenhed	EULAR 2022 - Copenhagen Varighed: 1 jun. 2022 → 4 jun. 2022

Konference

Konference	EULAR 2022
By	Copenhagen
Periode	01/06/2022 → 04/06/2022

Citationsformater

Hellamand, P., Van de Sande, M. G. H., Ørnbjerg, L. M., Klausch, T., Trokovic, N., Sokka-Isler, T., Van Vollenhoven, R., Nordström, D. C., Santos, MJ., Vieira-Sousa, E., Loft, A. G., Glintborg, B., Østergaard, M., Lindström, U., Wallman, J. K., Michelsen, B., Moeller, B., Micheroli, R., Codreanu, C., ... Van der Horst- Bruinsma, I. (2022). Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network. Annals of the Rheumatic Diseases 81 Suppl 1: 257. Abstract fra EULAR 2022, Copenhagen.

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network. / Hellamand, Pasoon; Van de Sande, Marleen G H; Ørnbjerg, Lykke Midtbøll et al.
2022. Annals of the Rheumatic Diseases 81 Suppl 1: 257 Abstract fra EULAR 2022, Copenhagen.

Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning › peer review

Hellamand, P, Van de Sande, MGH, Ørnbjerg, LM, Klausch, T, Trokovic, N, Sokka-Isler, T, Van Vollenhoven, R, Nordström, DC, Santos, MJ, Vieira-Sousa, E, Loft, AG, Glintborg, B , Østergaard, M, Lindström, U, Wallman, JK, Michelsen, B, Moeller, B, Micheroli, R, Codreanu, C, Moogosan, C, Laas, K, Roter, Z, Fagerli, KM, Tomsic, M, Castrejon, I, Pombo-Suarez, M, Gudbjörnsson, B, Love, T, Pavelka, K, Závada, J, Kenar, G, Yarkan-Tugsai, H, Hetland, ML & Van der Horst- Bruinsma, I 2022, 'Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network', EULAR 2022, Copenhagen, 01/06/2022 - 04/06/2022 s. Annals of the Rheumatic Diseases 81 Suppl 1: 257.

@conference{5f9cd59ce036437b83daeaa608026bd0,

title = "Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network",

abstract = "Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.",

author = "Pasoon Hellamand and {Van de Sande}, {Marleen G H} and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Thomas Klausch and N Trokovic and Tuulikki Sokka-Isler and {Van Vollenhoven}, R and D.C. Nordstr{\"o}m and MJ Santos and Elsa Vieira-Sousa and Loft, {A. G.} and Bente Glintborg and Mikkel {\O}stergaard and U Lindstr{\"o}m and Wallman, {Johan Karlsson} and Brigitte Michelsen and B. Moeller and Raphael Micheroli and Catalin Codreanu and C Moogosan and Karin Laas and Z Roter and Fagerli, {Karen Minde} and M Tomsic and I Castrejon and M Pombo-Suarez and B Gudbj{\"o}rnsson and T Love and K. Pavelka and Jakub Z{\'a}vada and G Kenar and H Yarkan-Tugsai and Hetland, {Merete Lund} and {Van der Horst- Bruinsma}, I",

note = "COPECARE; EULAR 2022 ; Conference date: 01-06-2022 Through 04-06-2022",

year = "2022",

language = "English",

pages = "Annals of the Rheumatic Diseases 81 Suppl 1: 257",

}

TY - ABST

T1 - Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

AU - Hellamand, Pasoon

AU - Van de Sande, Marleen G H

AU - Ørnbjerg, Lykke Midtbøll

AU - Klausch, Thomas

AU - Trokovic, N

AU - Sokka-Isler, Tuulikki

AU - Van Vollenhoven, R

AU - Nordström, D.C.

AU - Santos, MJ

AU - Vieira-Sousa, Elsa

AU - Loft, A. G.

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Lindström, U

AU - Wallman, Johan Karlsson

AU - Michelsen, Brigitte

AU - Moeller, B.

AU - Micheroli, Raphael

AU - Codreanu, Catalin

AU - Moogosan, C

AU - Laas, Karin

AU - Roter, Z

AU - Fagerli, Karen Minde

AU - Tomsic, M

AU - Castrejon, I

AU - Pombo-Suarez, M

AU - Gudbjörnsson, B

AU - Love, T

AU - Pavelka, K.

AU - Závada, Jakub

AU - Kenar, G

AU - Yarkan-Tugsai, H

AU - Hetland, Merete Lund

AU - Van der Horst- Bruinsma, I

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

AB - Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

M3 - Conference abstract for conference

SP - Annals of the Rheumatic Diseases 81 Suppl 1: 257

T2 - EULAR 2022

Y2 - 1 June 2022 through 4 June 2022

ER -

Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EuroSpA research collaboration network

Abstract

Konference

Fingeraftryk

Citationsformater